Drug
Dinaciclib clinical trials
Also written SCH 727965 and MK-7965.
- studies test it
- 17
- open now
- 0
- in phase 3
- 1
- first study started
- 2006
How studies write it
Studies that test it under each name
Development codes
- MK-7965
- 13
Studies by the year they started
17 studies that test it; most in 2009 (5)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 5 |
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 1 |
| 2016 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 7
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 9
National Cancer Institute (NCI) (8) · Merck Sharp & Dohme LLC (7) · Jo Chien (1) · AbbVie (1)
Often tested with
Tested in the same studies.
Pembrolizumab (2) · Veliparib (1) · Bortezomib (1) · Dexamethasone (1) · Epirubicin (1) · Ofatumumab (1) · MK 2206 (1) · Rituximab (1)
Studies
Open first, then newest update. How each study uses dinaciclib is read from its arms, and is right about nine times in ten.
Testing it · 17
- Dinaciclib in Treating Patients With Stage IV MelanomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT00937937Written as Dinaciclib
- Veliparib and Dinaciclib in Treating Patients With Advanced Solid TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01434316Written as Dinaciclib
- A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedPhase 1AbbVieNCT03484520Written as Dinaciclib
- Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast CancerCompletedPhase 1Jo ChienNCT01676753Written as Dinaciclib
- Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)TerminatedPhase 1Merck Sharp & Dohme LLCNCT02684617Written as dinaciclib
- Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedPhase 1National Cancer Institute (NCI)NCT01711528Written as Dinaciclib
- Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast CancerCompletedPhase 1National Cancer Institute (NCI)NCT01624441Written as Dinaciclib
- Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic LeukemiaCompletedPhase 1/2National Cancer Institute (NCI)NCT01515176Written as Dinaciclib
- Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by SurgeryCompletedPhase 1National Cancer Institute (NCI)NCT01783171Written as Dinaciclib
- Dinaciclib in Treating Patients With Stage III-IV MelanomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT01026324Written as dinaciclib
- A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)CompletedPhase 3Merck Sharp & Dohme LLCNCT01580228Written as Dinaciclib
- SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)TerminatedPhase 2Merck Sharp & Dohme LLCNCT00871546Written as SCH 727965
- SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)CompletedPhase 2Merck Sharp & Dohme LLCNCT00732810Written as SCH 727965
- Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)CompletedPhase 1Merck Sharp & Dohme LLCNCT00871663Written as SCH 727965
- A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)CompletedPhase 1Merck Sharp & Dohme LLCNCT01650727Written as Dinaciclib
- SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)TerminatedPhase 2Merck Sharp & Dohme LLCNCT00798213Written as SCH 727965
- Dinaciclib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 2National Cancer Institute (NCI)NCT01096342Written as dinaciclib
Given in every arm · 1 — dinaciclib is usual care beside what is tested
Codes
What other systems call dinaciclib · ClinicalTrials.gg INT005738
- MeSH (NLM) C553669dinaciclibOne source NLM
- UNII (FDA) 4V8ECV0NBQDINACICLIBConfirmed FDA, NLM, Wikidata
- Wikidata Q15723091dinaciclibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78854DinaciclibOne source FDA
- DrugBank DB12021One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C553669 | dinaciclib | One source NLM |
| UNII (FDA) | 4V8ECV0NBQ | DINACICLIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15723091 | dinaciclib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78854 | Dinaciclib | One source FDA |
| DrugBank | DB12021 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.